Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes
- 4 Downloads
To identify the association of type 2 diabetes (T2DM) and liver disease with elevated ALT and factors associated with increased ALT in patients with and without T2DM.
Design and setting
We performed a retrospective study in adults with ≥ 2 claims for blood tests recorded in the Medical Data Vision claims database between 2010 and 2016.
Patients were entered into T2DM and non-DM groups based on diagnosis and medication claim codes.
Primary outcome measure
The primary endpoint was the first follow-up ALT elevation over three times the normal value, and etiologies were categorized by subsequent diagnoses. We estimated the ALT elevation incidence and association with T2DM using Poisson regression and Cox proportional hazard models.
We identified 3161 cases of elevated ALT in 104,903 patients (follow-up, 280,659 patient-years). The age- and sex-adjusted incidence of elevated ALT in the T2DM group (13.47 per 1000 patient-years; 95% confidence interval (CI) 12.53–14.48) was significantly higher than that in the non-DM group (8.43 per 1000 patient-years; 95% CI 7.72–9.20, p < 0.0001). Compared to the non-DM group, the T2DM group had an approximately 3.5 times higher risk of fatty liver-related ALT elevation (adjusted hazard ratio (HR), 3.54; 95% CI 1.90–6.58). T2DM was not associated with an increased incidence of jointly elevated ALT and total bilirubin (adjusted HR, 0.94; 95% CI 0.77–1.15).
T2DM is strongly associated with increased liver enzymes secondary to fatty liver. The causes of liver enzyme abnormalities were not fully characterized due to a high proportion of unexplained ALT elevation.
KeywordsAlanine transaminase Diabetes mellitus Epidemiology Japan Liver diseases
We would like to thank Editage (http://www.editage.com) for editing and reviewing this manuscript for English language.
All authors contributed to the conceptualization of the study and preparation of the manuscript, including literature review (CHC), data analysis (CHC) and result interpretation (CHC and MS), and are responsible for the reported research. All the authors have read the manuscript and approved its submission.
This work was supported by Takeda, Japan.
Compliance with ethical standards
Conflicts of interest
CHC and MS are employees of Takeda. The authors declare they have no conflict of interest with respect to this research study and paper. The funder (Takeda, Japan) provided support in the form of salaries for authors (CHC, MS) and research materials only, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
As secondary database we used for research purposes contained anonymized data only, this article does not contain any studies with human or animal subjects performed by any of the authors. Patient informed consent was not required, because it is impossible to link the identifiers with external information.
- 2.Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician. 2005;71:1105–10.Google Scholar
- 19.Harvey R, Jankus DD, Mosley D. Random assignment of proxy event dates to unexposed individuals in observational studies: an automated technique using SAS®. 2012. https://www.mwsug.org/proceedings/2012/PH/MWSUG-2012-PH02.pdf. Accessed 6 Feb 2017.
- 20.US Department of Health and Human Services FDaA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry druginduced liver injury: premarketing clinical evaluation. 2009. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation Accessed 28 Feb 2017.